NATACYN

Manufacturer
Harrow Eye, LLC
Effective date
2025-10-30
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 22:03:13

Label at a glance#

ProductNATACYN
Active ingredientNATAMYCIN
Label structure16 sections

Indications and uses

NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug resp...

Dosage and administration

SHAKE WELL BEFORE USING. The preferred initial dosage in fungal keratitis is one drop of NATACYN™ (natamycin ophthalmic suspension) 5% instilled in the conjunctival sac at hourly or two-hourly intervals. The frequency of application can usually be reduced to one drop 6 to 8 times daily after the first 3 to 4 days. Therapy should generally be continued for 14 to 21 days or until there is resolution of active fungal...

Label contents#

Full prescribing information#

DESCRIPTION:

DESCRIPTION SECTION

NATACYN™ (natamycin ophthalmic suspension) 5% is a sterile, antifungal drug for topical ophthalmic administration. Each mL of NATACYN™ (natamycin ophthalmic suspension) contains: Active:natamycin 5% (50 mg). Preservative:benzalkonium chloride 0.02%. Inactive:sodium hydroxide and/or hydrochloric acid (neutralized to adjust the pH), purified water.

The active ingredient is represented by the chemical structure:

chemicalchemical

Established Name:Natamycin

Molecular Formula:C 33H 47NO 13

Molecular Weight:665.73 g/mol

Chemical Name:Stereoisomer of 22-[(3-amino-3,6-dideoxy- β-D-mannopyranosyl)oxy]-1,3,26- trihydroxy-12- methyl-10-oxo-6,11,28- trioxatricyclo[22.3.1.05,7] octacosa-8,14,16,18,20-pentaene-25- carboxylic acid.

Other:Pimaricin

The pH range is 5.0-7.5.

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

Natamycin is a tetraene polyene antibiotic derived from Streptomyces natalensis. It possesses in vitroactivity against a variety of yeast and filamentous fungi, including Candida, Aspergillus, Cephalosporium, Fusariumand Penicillium. The mechanism of action appears to be through binding of the molecule to the sterol moiety of the fungal cell membrane. The polyenesterol complex alters the permeability of the membrane to produce depletion of essential cellular constituents. Although the activity against fungi is dose-related, natamycin is predominantly fungicidal. Natamycin is not effective in vitroagainst gram-positive or gram-negative bacteria. Topical administration appears to produce effective concentrations of natamycin within the corneal stroma but not in intraocular fluid. Systemic absorption should not be expected following topical administration of NATACYN™ (natamycin ophthalmic suspension) 5%. As with other polyene antibiotics, absorption from the gastrointestinal tract is very poor. Studies in rabbits receiving topical natamycin revealed no measurable compound in the aqueous humor or sera, but the sensitivity of the measurement was no greater than 2 mg/mL.

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solanikeratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitroactivity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

NATACYN™ (natamycin ophthalmic suspension) 5% is contraindicated in individuals with a history of hypersensitivity to any of its components.

PRECAUTIONS: General.

GENERAL PRECAUTIONS SECTION

FOR TOPICAL OPHTHALMIC USE ONLY — NOT FOR INJECTION. Failure of improvement of keratitis following 7-10 days of administration of the drug suggests that the infection may be caused by a microorganism not susceptible to natamycin.

Continuation of therapy should be based on clinical re-evaluation and additional laboratory studies.

Adherence of the suspension to areas of epithelial ulceration or retention of the suspension in the fornices occurs regularly. Use only if the container is undamaged.

Information for Patients:

INFORMATION FOR PATIENTS SECTION

Do not touch dropper tip to any surface, as this may contaminate the suspension. Patients should be advised not to wear contact lenses if they have signs and symptoms of fungal blepharitis, conjunctivitis, and keratitis.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

There have been no long term studies done using natamycin in animals to evaluate carcinogenesis, mutagenesis, or impairment of fertility.

Pregnancy:

PREGNANCY SECTION

Animal reproduction studies have not been conducted with natamycin. It is also not known whether natamycin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. NATACYN ™(natamycin ophthalmic suspension) 5% should be given to a pregnant woman only if clearly needed.

Nursing Mothers:

LACTATION SECTION

It is not known whether these drugs are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when natamycin is administered to a nursing woman.

Pediatric Use:

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use:

GERIATRIC USE SECTION

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

The following events have been identified during post-marketing use of NATACYN ™(natamycin ophthalmic suspension) 5% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to their seriousness, frequency of reporting, possible causal connection to NATACYN™ (natamycin ophthalmic suspension) 5%, or a combination of these factors include: allergic reaction, change in vision, chest pain, corneal opacity, dyspnea, eye discomfort, eye edema, eye hyperemia, eye irritation, eye pain, foreign body sensation, parethesia, and tearing.

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

SHAKE WELL BEFORE USING. The preferred initial dosage in fungal keratitis is one drop of NATACYN™ (natamycin ophthalmic suspension) 5% instilled in the conjunctival sac at hourly or two-hourly intervals. The frequency of application can usually be reduced to one drop 6 to 8 times daily after the first 3 to 4 days. Therapy should generally be continued for 14 to 21 days or until there is resolution of active fungal keratitis. In many cases, it may be helpful to reduce the dosage gradually at 4 to 7 day intervals to assure that the replicating organism has been eliminated. Less frequent initial dosage (4 to 6 daily applications) may be sufficient in fungal blepharitis and conjunctivitis.

HOW SUPPLIED:

HOW SUPPLIED SECTION

NATACYN™ (natamycin ophthalmic suspension) 5% is a 15 mL fill packaged in a 15 mL amber glass bottle with a black closure. A flint glass dropper with a red plastic closure and a black rubber bulb are packaged separately in a clear plastic blister with Tyvek backing.

15 mL NDC82667-012-05

STORAGE:Store between 2°C to 24°C (36°F-75°F). Do not freeze. Avoid exposure to light and excessive heat.

Rx Only

SPL UNCLASSIFIED SECTION

Distributed by:

Harrow Eye, LLC™

Nashville, TN USA

Revised: 07/2024

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 82667-012-05

Harrow ®

Natacyn™

(natamycin ophthalmic suspension) 5%

Anti-Fungal Ophthalmic Suspension
Rx Only

15 mL

Sterile

Natacyn_Carton.jpgNatacyn_Carton.jpg

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
207100Natacyn 5 % Ophthalmic SuspensionPSN2
204451natamycin 5 % Ophthalmic SuspensionPSN2
207100natamycin 50 MG/ML Ophthalmic Suspension [Natacyn]SBD2
204451natamycin 50 MG/ML Ophthalmic SuspensionSCD2
207100Natacyn 5 % Ophthalmic SuspensionSY2
207100Natacyn 50 MG/ML Ophthalmic SuspensionSY2
204451natamycin 5 % Ophthalmic SuspensionSY2

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
NATAMYCIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeEAN-130382667012054GTIN-13: 0382667012054
EAN-13: 0382667012054
GTIN-12: 382667012054
UPC-A: 382667012054
GTIN storage (14 digits): 00382667012054
Natacyn_Carton.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
2e89db81-98c7-14a5-4bf2-ab0ee6489391Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
82667-012-05NATACYN1 in 1 CARTONSUSPENSION/ DROPS12
82667-012-05NATACYN15 mL in 1 BOTTLE, GLASSSUSPENSION/ DROPS152

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
82667-012-05ML - Milliliter82667-0127a3d566a-0724-4585-814f-83f53f62fbff12025-07-08

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
82667-01282667-012-05

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
12024-08-30full-release2026-05-31 21:16:13

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N050514-001NATACYNNATAMYCIN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 198274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 198287673890dc5c…
2021-03-12 10:30 UTC2021-03N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19825aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19828869cabd3fbd…
2020-11-12 02:37 UTC2020-11N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982c0c555d07b60…
2019-12-14 00:12 UTC2019-12N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19823f01610625f2…
2019-09-15 20:21 UTC2019-09N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982b00525d2431f…
2019-07-19 19:46 UTC2019-07N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19826a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19821c564ffb4f44…
2023-12-20 04:57 UTC2023-12N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19829b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19823f0d92c62455…
2023-05-13 08:27 UTC2023-05N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982053a50430f4f…
2023-01-26 05:58 UTC2023-01N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19823bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 19823a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N050514-001NATACYN5%SUSPENSION / OPHTHALMICRLD, RS, Approved before 1982f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
NATACYNNATAMYCINHarrow Eye, LLC20ede08c-0d39-dc65-e063-6394a90aa3e02025-10-30Adverse reactionsExact identifier
ndc (package): 82667-012-05
ndc (product): 82667-012
ndc11 (package): 82667001205
spl id: 42678f74-383b-962f-e063-6394a90a3315
spl set id: 20ede08c-0d39-dc65-e063-6394a90aa3e0

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.